Patients with need of platelet transfusion for any reason will participate in this study. Directly before the start of infusion and one hour after the end of platelet transfusion blood samples will be drawn and treated with different concentrations of Fibrinogen (a blood clotting factor) in-vitro. Blood samples with and without Fibrinogen/platelet transfusion will be compared. The study hypothesis is that treatment with Fibrinogen results in a better stabilisation of blood coagulation.
In total 300 patients with the need of platelet transfusion for whatever reason will be included when meeting the inclusion- and exclusion criteria. For all patients three visits are planned, where blood samples will be taken. The first blood samples will be taken directly before the start of platelet transfusion, the second 1 hour after the end of the platelet transfusion and the third after 24 hours. Untreated citrate and EDTA blood samples from Visit 1 will be serving as baseline for the coagulation testing. Further citrate blood samples from the first visit will be spiked with different concentrations of fibrinogen in vitro. Untreated citrate and EDTA blood samples will be taken 1 hour and 24 hours after platelet transfusion for comparison. Further citrate blood samples will be spiked with different concentrations of fibrinogen in vitro again 1 hour after platelet transfusion. In addition, randomly chosen samples will be analyzed using confocal microscopy. Routine coagulation analysis include activated partial thromboplastin time (aPTT), prothrombin time(PT), fibrinogen, blood coagulation factor thirteen (FXIII), thromboelastometry (ExTEM \& FibTEM) before and after platelet transfusion.
Study Type
INTERVENTIONAL
Allocation
NA
Masking
NONE
Enrollment
130
Patient with the need of a platelet transfusion, will have 4 intervention points. 1. directly before the start of the transfusion a blood sample will be drawn. 2. Patient receives the platelet transfusion. 3. One hour after the end of transfusion a second blood sample will be drawn. 4. 24 h after the end of the platelet transfusion a further bloos sample will be collected. The first two samples will be (beside blood cell counts) spiked in-vitro with different amounts of Human fibrinogen and blood clotting tests will be performed. The same with the 3. blood sample, but without spiking steps.
Central Institution for Blood Transfution and Immunology
Innsbruck, Tyrol, Austria
Department for Anesthesia and Intensive Care Medicine
Innsbruck, Tyrol, Austria
General and Surgical Intensive Care Medicine
Innsbruck, Tyrol, Austria
Faculty of Health Sciences, Centre for Haemophilia and Thrombosis, Aarhus University Hospital
Aarhus, Skejby, Denmark
difference in A30 (ExTEM®) between blood samples after in vitro spiking and compared to those blood samples obtained from the same patients after platelet transfusion
Time frame: 1 hour after platelet transfusion
Assessment of the difference in the response profile of Blood cell count (EDTA blood sample)
Time frame: before and 1 hour after platelet transfusion
Standard coagulation tests as aPTT, PT, fibrinogen and FXIII
Time frame: before and 1 hour after platelet transfusion
Further bleeding management system(ROTEM®)parameters
maximum clot firmness(MCF) clotting time(CT) clot formation time (CFT) lysis index 30 minutes after CT (L30)
Time frame: before and one hour after platelet transfusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Faculty of Health Sciences, Department for Anaesthesia and Critical Care Medicine
Aarhus, Skejby, Denmark